

SCIENCE NEWS®

The Weekly Newsmagazine of Science

A Science Service Publication
Volume 139, No. 3, January 19, 1991

E.G. Sherburne Jr.	Publisher
Patrick Young	Editor
Laurie Jackson	Managing Editor
Janice Rickerich	Production/Design Director
Bruce Bower	Behavioral Sciences
Ivan Amato	Chemistry/ Materials Science
Richard Monastersky	Earth Sciences
Janet Raloff	Environment/Policy
Ron Cowen	General Science
Kathy A. Fackelmann, Rick Weiss	Life Sciences/ Biomedicine
Ivars Peterson	Mathematics/Physics
Jonathan Eberhart	Space Sciences
Jennifer L. Miller	Editorial Assistant
Robert N. Langreth	Science Writer Intern
Liz Marshall	Books/Resource Manager
Donald R. Harless	Advertising/Business Manager

SCIENCE NEWS (ISSN 0036-8423) is published weekly on Saturday, except the last week in December, for \$34.50 for 1 year or \$58.00 for 2 years (foreign postage \$6.00 additional per year) by Science Service, Inc., 1719 N Street, N.W., Washington, D.C. 20036. Second-class postage paid at Washington, D.C., and additional mailing office. **POSTMASTER:** Send address changes to SCIENCE NEWS, 231 West Center Street, Marion, OH 43305. Change of address: Four to six weeks' notice is required — old and new addresses, including zip codes, must be provided.

Copyright © 1991 by Science Service, Inc. Title registered as trademark U.S. and Canadian Patent Offices. Printed in U.S.A.

Editorial and Business Offices:
1719 N St., N.W., Washington, D.C. 20036
(202-785-2255)

Republication of any portion of SCIENCE NEWS without written permission of the publisher is prohibited.

Subscription Department:
231 West Center St., Marion, OH 43305
For new subscriptions only, call 1-800-247-2160.

Letters

Immunologic pudding

I read with interest your report on our work on a peptide vaccine for asthma/hay-fever-type allergies ("New allergy vaccine brings relief to rats," SN: 12/1/90, p.341), the culmination of years of probing into the molecular pathology of anaphylactic antibodies.

Our "shaky" hypothesis, as NIH immunologist Henry Metzger refers to it, postulates that the IgE antibody plays an *active* role in initiating mediator release by providing a triggering signal to the sensitized mast cell as a consequence of allergen challenge. By using histamine-releasing polypeptides as models, we predicted the likely chemical characteristics of such a trigger site within the Fc region of the IgE molecule. We identified just one region within the CH4 domain of human IgE that possessed all these structural credentials. A synthetic peptide comprising this sequence was shown to initiate histamine release from nonsensitized mast cells in a manner closely resembling the regular IgE antibody-allergen-

This Week

- 36 Hot Year Prompts Greenhouse Concern
- 36 COBE maps the interstellar medium
- 37 Cold fusion still hasn't given up the ghost
- 37 Probing a trapped molecule's dynamics
- 38 Ancient city shows where cotton was king
- 38 Single-lung transplant saves failing hearts
- 38 AIDS vaccine: Safe, but does it work?
- 39 New worries over non-aspirin analgesics
- 39 Quasar erupts with relativistic flair

Research Notes

- 45 Biomedicine
- 45 Chemistry
- 47 Physics
- 47 Space Sciences

Articles

- 40 The Safer Sex?
Cover: Heart disease, traditionally viewed as a "male" malady, is the nation's number-one killer of men and women alike. In fact, women with the disease run an even higher risk than men of suffering a fatal heart attack or dying during coronary bypass surgery. Researchers are now trying to figure out why. (Illustration: Randy Fletcher)
- 42 Toxin to the Rescue

Departments

- 34 Books
- 35 Letters

Science Service Institution for the public understanding of science founded 1921; a nonprofit corporation.

Board of Trustees — *Chairman*, Glenn T. Seaborg; *Vice Chairman*, Gerald F. Tape; *Treasurer*, Willis Harlow Shapley; Joseph W. Berg Jr.; Robert W. Fri; David A. Goslin; J. David Hann; Milton Harris; Leon M. Lederman; Shirley M. Malcom; Elena O. Nightingale; Ben Patrusky; H. Guyford Stever; Deborah P. Wolfe.
Honorary Trustees — Edward Bliss Jr.; Bowen C. Dees; O.W. Riegel; John Troan.

President: E. G. Sherburne Jr.; Business Manager: Donald R. Harless.



pudding will be in the eating.

Denis R. Stanworth
Immunologist
University of Birmingham
Birmingham, England

Dandelion wine?

The studies implicating lecithin as an anti-cirrhotic phospholipid ("Soybean Lecithin May Prevent Cirrhosis," SN: 12/1/90, p.340) may vindicate the folkloric use of yellow flowers, in particular dandelions, as a treatment for yellow jaundice. Out of curiosity, I dipped into my "Father Nature's Farmacy" database after reading your story, to see which edible species had the most lecithin in the reports I had covered. To my surprise, dandelion flowers excelled, with a lecithin concentration of 29,700 parts per million (ppm). Soybeans had 15,000 to 25,000 ppm, mung

Letters continued on p.43

JANUARY 19, 1991

35

have achieved "quite remarkable success" in restoring vocal fluency, says Audrey L. Holland, a speech pathologist at the University of Pittsburgh School of Medicine. "By causing the vocal cords to become more flexible, [the toxin] allows speech to become more normal," she says.

Botulinum toxin may also offer relief for several other speech disorders, including some stuttering conditions, and for occupational hand dystonias — such as writer's or musician's cramp, in which intensive use of the hands leads to loss of control over the fingers. But while researchers feel optimistic about Type A's therapeutic potential, further studies must assess its effectiveness in these and other dystonias, the NIH panel concluded.

Physicians and psychologists once viewed dystonias as psychologically rooted illnesses, but scientists now believe that some of these disorders stem from an abnormality in the basal ganglia, an area of the brain responsible for smoothness and coordination of movement. The defect could be genetic, a consequence of environmental damage or a result of disease.

Except in certain cases of eye misalignment, Type A botulinum toxin provides only temporary, symp-

tomatic relief "and does not address the disturbance in the central nervous system [underlying these disorders]," Duvoisin says. Because new nerve endings sprout after several months — reestablishing communication with the muscles — and the dysfunctional nerve endings eventually recover as well, patients require periodic injections. But the temporary nature of the therapy "is in some ways an advantage," Duvoisin says, "because the toxin's effect does reverse in time, so that there is some protection against overtreatment."

Dystonias have conventionally been treated with other drugs, and sometimes with surgery to sever or remove the troublesome nerves. The NIH panel described both approaches as "minimally effective." Past experience has shown that operations to correct dystonias not only are irreversible and sometimes unpredictable, but also carry the risk of disfigurement for what may be short-lived benefits.

For a patient with blepharospasm, surgical destruction of the nerves causing spasmodic eyelid closings costs \$10,000 to \$14,000, says O.G. Bruce, former president of the Benign Essential Blepharospasm Research Foundation, Inc., in Beaumont, Tex.

In comparison, treatment with Type A botulinum toxin costs \$400 to \$1,800 per visit, depending on dosage; patients usu-

ally require three or four injections a year. While these expenses do, in time, exceed the cost of surgery, Bruce points out that an operation doesn't provide a full cure either and often requires follow-up drug therapy.

Moreover, some dystonias cannot be treated by surgery because the affected muscles lie in areas too difficult or risky to operate on, such as the neck. In contrast, doctors can easily inject botulinum toxin almost anywhere. "That's really what's so wonderful about [the treatment]," Johnson says.

A permanent toxin-based therapy may lie upon the distant horizon. At least one researcher hopes to improve Type A's therapeutic potential by manipulating the molecule.

In unpublished experiments, Simpson has engineered a new agent by removing the toxin's cell-poisoning region and inserting a deadlier substitute: a cell-killing fragment, isolated from a plant toxin called ricin, that works by blocking the cell's ability to make protein. If, when injected, this modified Type A toxin successfully binds and kills overstimulated nerve endings in patients with dystonias, it might provide a one-shot cure, he says.

"Nature has provided us with a starting material [in botulinum toxin]," Simpson says. "But I think if we re-engineer the toxin, we can come up with even better therapeutic agents." □

Letters continued from p.35

beans 16,000 and peanuts 5,000 to 7,000.

Maybe we should serve more soybeans, mung beans or peanuts with our beer, or else switch to dandelion wine. If I were concerned about cirrhosis, I'd up my intake of dandelions, milk thistle and artichokes, all of which contain hepatoprotective compounds. Or maybe I'd just add dandelion flowers to a bean paté.

James A. Duke

Economic Botanist

USDA Agricultural Research Service

Beltsville, Md.

Refuge from refuse

John Gillis (Letters, SN: 11/24/90, p.323) asks, "Can anyone seriously think that this vastly empty country of ours is lacking in space for trash disposal?"

True, my corner of rural America is devoid of the swarm of humanity that fills Mr. Gillis' hometown of New York City. But it is filled with wildlife and flowers, and with trees that give us oxygen to breathe and paper for publications such as this. There is more to an ecology than just human presence.

I agree with Mr. Gillis on one point: The real disposal problem of today is political, not physical. It is the political problem of persuading everyone to accept responsibility for the consequences of their own consumption, rather than expecting that they can dump those consequences in someone else's (apparently) empty backyard. We need to work on the technology to solve that one, so that I don't have to trade my wildflowers and wild animals for city dwellers' trash and rats and noxious

chemicals leaking into the groundwater. Maybe we can even come up with something that will let New York City keep its trash at home rather than barging it all over the world.

As a member of our town landfill committee, organized a few years ago when local landfills were almost full, I conceived the plans that became our recycling center. I assure you that even with apparently abundant space, rural areas still have problems disposing of waste. Burying it is not the answer, and for that and all other solutions, the technology and economics are really not congenial.

Bruce McCulley

Troy, N.H.

Mr. Gillis may be correct when he reasons that "garbage disposal has never been a major engineering problem." However, his attempt to place the blame on the "not-in-my-backyarders" fails to tell the whole story.

Landfills leak, even those with engineered liners and leachate collection systems. Even the EPA has admitted this. Alas, though garbage disposal may not be a major engineering problem, it is a major environmental problem — and if the political process stimulated by those who sponsor a "not-in-my-backyard" philosophy causes us to rethink the way in which we dispose of our wastes, and causes us to rely upon more benign forms of disposal such as recycling and composting, then we as a country with vast resources of land will be in a much better position to pass those resources on to the next generation of garbage producers.

Paul G. Beaulieu

Granby, Mass.

Civilization's colossal creation

Staten Island's Fresh Kills landfill is not only the biggest landfill in the world ("Big dig' unearths clues to garbage decay," SN: 11/24/90, p.324). By the time you read this, it will be the largest human-made structure of any kind, surpassing even the Great Wall of China. Its 2.3 billion-plus cubic feet equals the displacement of the Great Wall, and every new "baggie" expands its record.

How sad.

K.A. Borishkin
Bellingham, Mass.

Glaucoma and beyond

While some cases of glaucoma do involve headaches, halos and blurred vision, as anecdotally described in "Eyeing the Optic Nerve" (SN: 11/24/90, p.330), readers should recognize that the majority of cases exhibit no symptoms aside from a barely perceptible, gradual loss of peripheral vision.

Mrs. R.L. Border
Las Vegas, Nev.

The laser techniques devised by Dr. Weinreb promise new benefits beyond the measurement of retinal changes in glaucoma. This noninvasive technology could aid in the assessment of degenerative changes that signal the onset or progression of a variety of retinal diseases, giving physicians a new tool with possible wide application in the diagnosis and management of many ocular disorders.

David F. Weeks
President, Research to Prevent Blindness, Inc.
New York, N.Y.